Pharmacological stabilization of intracranial aneurysms in mice: a feasibility study

Document Type

Article

Abstract

BACKGROUND AND PURPOSE: An increasing number of unruptured intracranial aneurysms are being detected, partly due to the increased use of brain imaging techniques. Pharmacological stabilization of aneurysms for the prevention of aneurysmal rupture could potentially be an attractive alternative approach to clipping or coiling in patients with unruptured intracranial aneurysms. We have developed a mouse model of intracranial aneurysm that recapitulates key features of intracranial aneurysms. In this model, subarachnoid hemorrhage from aneurysmal rupture causes neurological symptoms that can be easily detected by a simple neurological examination. Using this model, we tested whether anti-inflammatory agents such as tetracycline derivatives, or a selective inhibitor of matrix metalloproteinases-2 and -9 (SB-3CT), can prevent the rupture of intracranial aneurysms. METHODS: Aneurysms were induced by a combination of induced hypertension and a single injection of elastase into the cerebrospinal fluid in mice. Treatment with minocycline, doxycycline, or SB-3CT was started 6 days after aneurysm induction. Aneurysmal rupture was detected by neurological symptoms and confirmed by the presence of intracranial aneurysms with subarachnoid hemorrhage. RESULTS: Minocycline and doxycycline significantly reduced rupture rates (vehicle versus doxycycline=80% versus 35%, P<0.05; vehicle versus minocycline=73% versus 24%, P<0.05) without affecting the overall incidence of aneurysms. However, SB-3CT did not affect the rupture rate (62% versus 55%, P=0.53). CONCLUSIONS: Our data established the feasibility of using a mouse model of intracranial aneurysm to test pharmacological stabilization of aneurysms. Tetracycline derivatives could be potentially effective in preventing aneurysmal rupture.

Medical Subject Headings

Aneurysm, Ruptured (drug therapy, pathology); Animals; Blood Pressure (drug effects); Disease Models, Animal; Doxycycline (therapeutic use); Feasibility Studies; Gelatinases (metabolism); Heterocyclic Compounds, 1-Ring (therapeutic use); Intracranial Aneurysm (drug therapy, pathology); Male; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Minocycline (therapeutic use); Neurologic Examination; Protease Inhibitors (therapeutic use); Subarachnoid Hemorrhage (drug therapy, pathology); Sulfones (therapeutic use); Survival Analysis; Tetracyclines (therapeutic use)

Publication Date

9-1-2012

Publication Title

Stroke

E-ISSN

1524-4628

Volume

43

Issue

9

First Page

2450

Last Page

6

PubMed ID

22798328

Digital Object Identifier (DOI)

10.1161/STROKEAHA.112.659821

Link to Full Text

Share

COinS